PepGen Inc. Logo

PepGen Inc.

Biotech using an EDO platform to treat genetic neuromuscular & neurological diseases.

PEPG | NDAQ

Overview

Corporate Details

ISIN(s):
US7133171055
LEI:
Country:
United States of America
Address:
1 MARINA PARK DRIVE, SUITE 900, 2210 BOSTON
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

PepGen Inc. is a clinical-stage biotechnology company focused on developing a new generation of disease-modifying therapies. The company is creating a pipeline of therapeutics aimed at treating severe, genetic neuromuscular and neurological diseases by targeting their root cause. PepGen utilizes its proprietary Enhanced Delivery Oligonucleotide (EDO) platform to optimize the delivery of therapeutic oligonucleotides, with the goal of advancing transformative treatments for patients with devastating conditions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all PepGen Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for PepGen Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for PepGen Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Nexxen International Ltd. Logo
End-to-end programmatic ad platform for advertisers, agencies, & publishers, specializing in video & CTV.
United States of America NEXN
NFL Biosciences Logo
Develops botanical drug candidates to treat smoking and alcohol addictions.
France ALNFL
NGS Group Logo
Nordic staffing & recruitment for healthcare, education, and social services sectors.
Sweden NGS
Nihon M&A Center Holdings Inc. Logo
M&A advisory firm specializing in brokerage and consulting for Japanese SMEs, including cross-border deals.
Japan 2127
Noile-Immune Biotech Inc. Logo
Developing PRIME technology-enhanced CAR-T cell immunotherapies for treating solid tumors.
Japan 4893
NRGene Technologies Ltd. Logo
AI-powered genomic analysis software to accelerate and optimize plant and animal breeding.
Israel NRGN
Nuvectis Pharma, Inc. Logo
Clinical-stage biopharma developing precision medicines for serious oncological conditions.
United States of America NVCT
Nykode Therapeutics ASA Logo
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
Norway NYKD
Ocugen, Inc. Logo
Develops gene/cell therapies and vaccines, specializing in blindness and public health.
United States of America OCGN
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
Switzerland OCS

Talk to a Data Expert

Have a question? We'll get back to you promptly.